6 Minute Read
Our latest blog offers a detailed breakdown of the new manufacturer discount program invoices and assesses the implications of adding Part B drugs to the IPAY 2028 and MFP.
2 Minute Read
The pharmaceutical industry stands at a pivotal juncture, navigating a complex landscape marked by evolving drug archetypes, escalating costs, and stringent regulations. In this dynamic environment, the ability to...
2 Minute Read
The pharmaceutical landscape, particularly during launch, is drowning in data. Specialty Pharmacy (SP) and Specialty Distributor (SD) data streams are critical lifelines, offering insights into prescribing behavior, patient access,...
7 Minute Read
The 340B program stands out as one of the most dynamic and complex government programs. We will explore how and why we got here.
2 Minute Read
The pharmaceutical industry faces increasing difficulty accurately calculating and reporting government prices due to stringent regulations and recent complex changes.
3 Minute Read
Explore the best practice recommendations regarding compliance for SPTR.
4 Minute Read
Expert opinions from a recent price transparency congress on reporting, remediation, and ways to manage state price transparency now and in the future.
4 Minute Read
This month we discuss COVID-19 vaccine mandates, the recent HHS drug discount ruling, and Medicare drug price reforms.
4 Minute Read
We discuss the Biden administration's plan for combatting high drug prices, the new PBM public law reporting cycle, and MA and Part D rule for 2022.